Central Indiana Corporate Partnership Inc

What it reported doing in 2025

Agrinovus Indiana is the state's initiative focused on advancing the agbiosciences sector as a nationally recognized leader through education, research and talent development; strategic collaborations among corporations, industry associations, government and universities; the creation and support of new companies; and branding and targeted promotions to elevate the sector. Agrinovus Indiana's charitable and educational activities are funded through cicp foundation. Visit www.agrinovusindiana.com. Agrinovus Indiana focused on speeding the pace of agbioscience innovation in 2025, growing the reach of its ecosystem and helping transform bold ideas into real-world impact. Across agrinovus' focus areas, progress was accelerated through startups and founders stepping onto bigger stages, new students and young professionals finding pathways to careers in agbioscience, and milestone industry announcements that will shape the state of Indiana for years to come. Biocrossroads is Indiana's life sciences initiative that fosters public-private collaboration by uniting a diverse range of academic, industry, and philanthropic stakeholders, all collectively focused on advancing Indiana's life sciences sector. Committed to supporting the growth of capital investments and talent development, biocrossroads provides support to both existing and new life sciences enterprises, including the Indiana health information exchange, orthoworx, and the Indiana biosciences research institute. Biocrossroads champions the advancement of cutting-edge research and development, plays a crucial role in building and nurturing a robust talent pipeline, and is dedicated to establishing Indiana as a thriving hub for life sciences manufacturing. Biocrossroads' charitable and educational activities are funded through cicp foundation. Visit www.biocrossroads.com. 2025 marked a defining moment for Indiana's life sciences sector. It was a year shaped not by a single breakthrough, but by years of intentional coordination across research, industry, government, and philanthropy. In july, Indiana was officially designated the radiopharmaceutical capital of the world, a milestone that reflected sustained investment, academic leadership, and ecosystem alignment across the state. Indiana's growing influence was further recognized in november when bio international's ceo visited the state as part of a national tour of leading life sciences regions. The visit affirmed what industry leaders increasingly see: Indiana's life sciences ecosystem is not only productive and globally competitive, but also highly collaborative and strategically aligned. Biocrossroads has played a central role in building those connections by bringing together stakeholders, elevating shared priorities, and amplifying Indiana's story on national and international stages.

Financial Efficiency

• Mission deployment rate: Limited
• Program expense ratio: Limited
• Fundraising efficiency: Limited

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 64th percentile among comparable filings
• Pay-setting controls: 5 of 6 controls in place; rating input score 83
  • Compensation committee: Pass
  • Independent consultant: Pass
  • Other Form 990s reviewed: Pass
  • Written employment contract: Missing
  • Compensation survey or study: Pass
  • Board or committee approval: Pass
• Foreign activity oversight: Limited
• Grant itemization coverage: 100%; rating input score 100; 76th percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Yes; rating input score 100

Accountability

• Independent voting board: 100%; rating input score 100; 64th percentile among comparable filings
• Governance controls: 9 of 9 controls in place; rating input score 100
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: 2.9%; rating input score 36; 36th percentile among comparable filings
• Total-asset coverage ratio: 0.83; rating input score 24; 24th percentile among comparable filings
• Liabilities to assets ratio: 0.1; rating input score 66; 66th percentile among comparable filings
• Officer compensation ratio: 52.6%; rating input score 0; 0th percentile among comparable filings

Growth

• Program expense growth: Limited
• Revenue growth: 6.4% per year; rating input score 100; 53rd percentile among comparable filings
• Asset growth: 8.7% per year; rating input score 100; 61st percentile among comparable filings